The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Makes you wonder why the FDA wants to protect GSK and allow the US consumer to continue being ripped off in a monopoly situation. If I was a cynic I'd say that some palms are being...…….no, no.no, I wont say that.
Maybe I should sell VEC and buy GSK again?
Should have been viewed as good news for us & HIK but the Market clearly considers that Mylans second failure is an indication that we will fail at the second hurdle too, delaying the fateful day further.An optimist would suggest that we wont make that mistake second time around & we may then have some earlier mover advantage in the generic Advair stakes.The Market is struggling to see any positives in poor old Vec , endorsing my view in my previous posting.
(Reuters) - Mylan NV said on Wednesday that U.S. health regulators were unable to approve its generic version of GlaxoSmithKline’s blockbuster inhaled lung drug Advair for the second time, as they found “minor deficiencies” in the treatment. Shares of Mylan fell 4.5 percent to $39.80 after the bell. Mylan did not provide details on the nature of the deficiencies cited by the U.S. Food And Drug Administration and it remains unclear whether the company will be able to resolve them and get approval this year. The FDA has declined to approve several Advair knock-offs in the past from drugmakers including Novartis AG, Hikma Pharmaceuticals and Mylan itself, whose generic was rejected last year. “I don’t think this comes as a big surprise ... people realize these are all very difficult-to-make products and they’re going to go through a couple of rounds at the FDA,” Leerink analyst Ami Fadia told Reuters. “They (Mylan) will actually still be at least one year ahead of competition if they got approval this year.” The news bodes well for GSK, which has dominated the lung drug market for decades and was bracing for competition by mid-2018. Even as the British drugmaker puts more marketing muscle on its newer lung drugs, GSK reported revenue of 3,130 million pounds ($4.19 billion) from Advair last year. Mylan said here it expects to receive a formal complete response letter, typically issued to outline concerns and conditions that must be addressed to gain U.S. approval, from the FDA on June 27 and would determine what impact, if any, it would have on its full-year forecast. https://www.reuters.com/article/us-mylan-advair/fda-finds-deficiencies-in-mylans-generic-advair-idUSKBN1J931R